Indication
Diphtheria
12 clinical trials
42 products
Clinical trial
Single Blind, Randomized, Comparative, Multicentre Clinical Trial of the Immunogenicity and Safety of Booster Immunization With Bivalent Vaccine Against Tetanus and Diphtheria CLODIVAC (IBSS Biomed S.A.) and Td-Impfstoff Mérieux (Sanofi Pasteur) in Healthy Adults.Status: Active (not recruiting), Estimated PCD: 2024-03-04
Product
ClodivacProduct
Td-Impfstoff MerieuxClinical trial
A Randomized, Blinded, Controlled Phase I Clinical Trial for Preliminary Evaluation of the Safety and Immunogenicity of Adsorbed Cell-free DPT Vaccine (for People Aged 6 Years and Above)Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
A Randomized, Blinded, Positive Vaccine-controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of DTcP in Infants and Children at 2 and 3 Months of AgeStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Product
DTcPProduct
DTaPProduct
Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP)Product
DTaP-IPV-HibClinical trial
A Phase IV, Single-blind, Randomised, Controlled, Multi-country Study to Evaluate the Immunogenicity and Safety of GSK's Infanrix Hexa (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis (DTaP5-HBV-IPV Hib), When Administered Intramuscularly According to a 2-, 4- and 12-month Schedule in Healthy Infants and ToddlersStatus: Completed, Estimated PCD: 2022-07-25
Product
DTaP5-HBV-IPV-HibProduct
PPV23Product
Td-ImpfstoffProduct
DTPa-HBV-IPV/HibClinical trial
A Randomized, Blinded, Parallel Controlled Phase 3 Clinical Study to Evaluate the Safety and Immunogenicity of the Diphtheria, Tetanus and Three-components Acellular Pertussis Combined Vaccine, Adsorbed in Healthy Infants at the Age of 2 Months and 3 MonthsStatus: Active (not recruiting), Estimated PCD: 2023-09-22
Product
LBVDClinical trial
A Prospective, Multi-national, Multi-center, Open-label, Randomized, Active-controlled, Parallel-group, Operationally Seamless Phase 2/3 Clinical Study to Evaluate the Immunogenicity and Safety of LBVD, a Fully Liquid Hexavalent Diphtheria-Tetanus-Whole Cell Pertussis-Hepatitis B-poliomyelitis (Inactivated)-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, Given to Healthy Infants at 6-, 10-, and 14-week of Age as Primary SeriesStatus: Not yet recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Randomized,Blind, Positive-controlled Phase I Clinical Trial to Preliminary Evaluate the Safety of DTcP Vaccine in Healthy Children Aged Between 2 Months and 6 YearsStatus: Completed, Estimated PCD: 2021-10-27
Product
Diphtheria, Tetanus, Pertussis, Poliomyelitis and Haemophilus Influenzae Type B Conjugate VaccineClinical trial
A Multinational, Multicenter, Randomized, Comparative, Open-label, Phase 3 Study to Assess the Immunogenicity and Safety of DTaP-IPV (Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus) Vaccine Administered to Healthy InfantsStatus: Completed, Estimated PCD: 2017-12-19
Product
DTaP vaccine + IPV vaccineClinical trial
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and InfantsStatus: Completed, Estimated PCD: 2023-08-10
Product
Varicella Virus Vaccine LiveProduct
Rotavirus VaccineProduct
Hepatitis B VaccineClinical trial
Immune Response to Pertussis After Vaccination With a Tdap-IPV Booster Vaccine in Children in the Republic of South Africa: Effect of Homologous and Heterologous Pertussis Vaccination Priming BackgroundStatus: Completed, Estimated PCD: 2023-01-11
Product
DTaP-IPVProduct
DTaP-HepB-IPV-HibProduct
DTaP-HepB-IPV-Hib vaccineClinical trial
A Single-center, Randomized, Active-controlled, Parallel-group, Double-blind, Phase I Clinical Trial to Evaluate Safety and Immunogenicity of Hexavalent Vaccine (APV006) in Healthy AdultsStatus: Not yet recruiting, Estimated PCD: 2023-10-31
Clinical trial
To Evaluate Safety and Preliminary Immunogenicity of the Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine in Children Aged 2 Months to 6 Years: A Randomized, Blinded, Active-controlled Phase I Clinical TrialStatus: Recruiting, Estimated PCD: 2024-12-15
Product
DTacPProduct
DTProduct
PENTAXIM